On November 16, 2023 Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, reported that the first patient has been dosed in a Phase 1/2 clinical trial of ALE.C04, a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of CLDN1+ tumors (Press release, Alentis Therapeutics, NOV 16, 2023, View Source [SID1234637725]). The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part of Keck Medicine of USC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The open-label, multi-center, Phase 1/2 clinical trial (NCT06054477) will investigate ALE.C04 as a single agent and in combination with pembrolizumab (anti-PD-1 antibody) in 220 adults with recurrent or metastatic (R/M) head and neck squamous cell carcinoma. Endpoints include safety, tolerability, pharmacokinetics and anti-tumor efficacy.
"ALE.C04 is a first-in-class antibody for treating cancer and has shown much potential in preclinical models," said Luigi Manenti, MD, Chief Medical Officer of Alentis. "ALE.C04 is designed to kill CLDN1+ tumor cells directly and to break the check-point inhibitor treatment resistance by restoring immune cell trafficking."
Jacob Thomas, MD, principal investigator on the trial at USC Norris and Assistant Professor of Medicine at Keck School of Medicine of USC added, "Patients with R/M HNSCC have poor outcomes, and novel effective therapies are needed in this setting. The mechanism of action and preclinical data for ALE.C04 provide sound scientific rationale for its evaluation in HNSCC."
Prof. Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital said, "This first-in-human trial will provide valuable information on ALE.C04 as a monotherapy and in combination with anti-PD-1 treatment. I am looking forward to the data and to developing ALE.C04 for other CLDN1+ tumors including colorectal cancer."
About ALE.C04
ALE.C04 is a first-in-class monoclonal antibody developed to specifically target exposed CLDN1 on cancer cells. This investigational antibody is designed to treat cancer in two ways: remodeling of the extracellular matrix, leading to improved NK and T-cell trafficking and direct tumor cell killing through the effector function. This unique mechanism of action provides ALE.C04 with therapeutic potential as a monotherapy and in combination. ALE.C04 received Fast Track designation from the Food and Drug Administration for the treatment of CLDN1+ HNSCC.
About HNSCC
Head and neck squamous cell carcinoma, or HNSCC, is the 6th most common cancer worldwide and because the number of cases is quickly rising, safer and more effective treatments are urgently needed. Despite advances in treatment, the 5-year survival rate remains at about 57%.